We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Astellas Pharma Inc (PK) | USOTC:ALPMY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06 | -0.61% | 9.71 | 9.46 | 9.91 | 9.85 | 9.64 | 9.735 | 89,294 | 21:01:32 |
From Mar 2023 to Mar 2025
By Colin Kellaher
Poseida Therapeutics shares surged Monday after the clinical-stage biopharmaceutical company said it would receive a $50 million investment from Astellas that will help support its strategic and operational plans.
Shares of the San Diego company were recently changing hands at $2.56, up about 57%.
Poseida said Astellas is taking an 8.8% stake in the company by investing $25 million for more than 8.33 million shares at $3 apiece, an 84% premium to Friday's closing price of $1.63.
Astellas is also paying $25 million for a right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1, Poseida's allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Posieda said the investment, along with cost-control measures it has implemented, extend its cash runway into early 2025.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 07, 2023 10:26 ET (14:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astellas Pharma (PK) Chart |
1 Month Astellas Pharma (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
